The metabolic impact of combined oral contraceptive pills in women with and without polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) is a common hormonal disorder in women which is associated with health complications including diabetes and cardiovascular risk factors. Combined oral contraceptive pills (COCPs) are the first-line pharmacological treatment for women with PCOS as they improve typical PCOS symptoms. Previous research has linked COCPs with increased diabetes risk and worsened cholesterol levels which raised concerns regarding their usage in women with PCOS who are already prone to these disorders. However, research findings regarding COCPs usage on the actual development of diabetes and high cholesterol in women with and without PCOS are inconsistent and deserves further evaluation.